[1]
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144, 646-674.
[2]
Bronowicka-Klys, D.E.; Lianeri, M.; Jagodzinski, P.P. The role and impact of estrogens and xenoestrogen on the development of cervical cancer. Biomed. Pharmacother., 2016, 84, 1945-1953.
[3]
Son, J.; Park, Y.; Chung, S.H. Epithelial oestrogen receptor alpha is dispensable for the development of oestrogen-induced cervical neoplastic diseases. J. Pathol., 2018, 245, 147-152.
[4]
Auborn, K.J.; Woodworth, C.; DiPaolo, J.A.; Bradlow, H.L. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int. J. Cancer, 1991, 49, 867-869.
[5]
Bosland, M.C. Sex steroids and prostate carcinogenesis: Integrated, multifactorial working hypothesis. Ann. N. Y. Acad. Sci., 2006, 1089, 168-176.
[6]
Brake, T.; Lambert, P.F. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc. Natl. Acad. Sci. USA, 2005, 102, 2490-2495.
[7]
Chung, S.H.; Shin, M.K.; Korach, K.S.; Lambert, P.F. Requirement for stromal estrogen receptor alpha in cervical neoplasia. Horm. Cancer, 2013, 4, 50-59.
[8]
Herber, R.; Liem, A.; Pitot, H.; Lambert, P.F. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J. Virol., 1996, 70, 1873-1881.
[9]
Prossnitz, E.R.; Barton, M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol., 2011, 7, 715-726.
[10]
Chung, S.H.; Wiedmeyer, K.; Shai, A.; Korach, K.S.; Lambert, P.F. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res., 2008, 68, 9928-9934.
[11]
Ramachandran, B. Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis. Endocr. Relat. Cancer, 2017, 24, R99-R108.
[12]
Riera-Leal, A.; De Arellano, R.A.; Ramirez-Lopez, I.G.; Lopez-Pulido, E.I.; Rodriguez, D.J.R.; Macias-Barragan, J.G.; Ortiz-Lazareno, P.C.; Jave-Suarez, L.F.; Artaza-Irigaray, C.; Arreola, T.S.; Montoya-Buelna, M.; Munoz-Valle, J.F.; Pereira-Suarez, A.L. Effects of 60 kDa prolactin and estradiol on metabolism and cell survival in cervical cancer: Coexpression of their hormonal receptors during cancer progression. Oncol. Rep., 2018, 40, 3781-3793.
[13]
Friese, K.; Kost, B.; Vattai, A.; Marme, F.; Kuhn, C.; Mahner, S.; Dannecker, C.; Jeschke, U.; Heublein, S. The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer. J. Cancer Res. Clin. Oncol., 2018, 144, 13-19.
[14]
Zhang, Q.; Wu, Y.Z.; Zhang, Y.M.; Ji, X.H.; Hao, Q. Activation of G-protein coupled estrogen receptor inhibits the proliferation of cervical cancer cells via sustained activation of ERK1/2. Cell Biochem. Funct., 2015, 33, 134-142.
[15]
Fitzwalter, B.E.; Thorburn, A. Recent insights into cell death and autophagy. FEBS J., 2015, 282, 4279-4288.
[16]
Chimento, A.; Casaburi, I.; Bartucci, M.; Patrizii, M.; Dattilo, R.; Avena, P.; Ando, S.; Pezzi, V.; Sirianni, R. Selective GPER activation decreases proliferation and activates apoptosis in tumor leydig cells. Cell Death Dis., 2013, 4, e747.
[17]
Chimento, A.; Casaburi, I.; Rosano, C.; Avena, P.; De Luca, A.; Campana, C.; Martire, E.; Santolla, M.F.; Maggiolini, M.; Pezzi, V.; Sirianni, R. Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Mol. Nutr. Food Res., 2014, 58, 478-489.
[18]
Bopassa, J.C.; Eghbali, M.; Toro, L.; Stefani, E. A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am. J. Physiol., 2010, 298, H16-H23.
[19]
Okamoto, M.; Mizukami, Y. GPER negatively regulates TNFalpha-induced IL-6 production in human breast cancer cells via NF-kappaB pathway. Endocr. J., 2016, 63, 485-493.
[20]
Childs, B.G.; Baker, D.J.; Kirkland, J.L.; Campisi, J.; van Deursen, J.M. Senescence and apoptosis: Dueling or complementary cell fates? EMBO Rep., 2014, 15, 1139-1153.
[21]
Chimento, A.; Sirianni, R.; Casaburi, I.; Zolea, F.; Rizza, P.; Avena, P.; Malivindi, R.; De Luca, A.; Campana, C.; Martire, E.; Domanico, F.; Fallo, F.; Carpinelli, G.; Cerquetti, L.; Amendola, D.; Stigliano, A.; Pezzi, V. GPER agonist G-1 decreases Adrenocortical Carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget, 2015, 6, 19190-19203.
[22]
Imesch, P.; Samartzis, E.P.; Dedes, K.J.; Fink, D.; Fedier, A. Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells. Fertil. Steril., 2013, 100, 770-776.
[23]
Lappano, R.; Rosano, C.; De Marco, P.; De Francesco, E.M.; Pezzi, V.; Maggiolini, M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell. Endocrinol., 2010, 320, 162-170.
[24]
Son, J.; Park, J.W.; Lambert, P.F.; Chung, S.H. Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice. Carcinogenesis, 2014, 35, 489-496.
[25]
Ramirez De Arellano, A.; Riera Leal, A.; Lopez-Pulido, E.I.; Gonzalez-Lucano, L.R.; Macias Barragan, J.; Del Toro Arreola, S.; Garcia-Chagollan, M.; Palafox-Sanchez, C.A.; Munoz-Valle, J.F.; Pereira-Suarez, A.L.A. 60 kDa prolactin variant secreted by cervical cancer cells modulates apoptosis and cytokine production. Oncol. Rep., 2018, 39, 1253-1260.
[26]
Cheng, S.B.; Graeber, C.T.; Quinn, J.A.; Filardo, E.J. Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids, 2011, 76, 892-896.
[27]
Kampa, M.; Pelekanou, V.; Notas, G.; Stathopoulos, E.N.; Castanas, E. The estrogen receptor: Two or more molecules, multiple variants, diverse localizations, signaling and functions. Are we undergoing a paradigm-shift as regards their significance in breast cancer? Hormones, 2013, 12, 69-85.
[28]
De Francesco, E.M.; Pellegrino, M.; Santolla, M.F.; Lappano, R.; Ricchio, E.; Abonante, S.; Maggiolini, M. GPER mediates activation of HIF1alpha/VEGF signaling by estrogens. Cancer Res., 2014, 74, 4053-4064.
[29]
Otto, C.; Rohde-Schulz, B.; Schwarz, G.; Fuchs, I.; Klewer, M.; Brittain, D.; Langer, G.; Bader, B.; Prelle, K.; Nubbemeyer, R.; Fritzemeier, K.H. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology, 2008, 149, 4846-4856.
[30]
Scaling, A.L.; Prossnitz, E.R.; Hathaway, H.J. GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm. Cancer, 2014, 5, 146-160.
[31]
Wang, D.; Hu, L.; Zhang, G.; Zhang, L.; Chen, C. G protein-coupled receptor 30 in tumor development. Endocrine, 2010, 38, 29-37.
[32]
Sanden, C.; Broselid, S.; Cornmark, L.; Andersson, K.; Daszkiewicz-Nilsson, J.; Martensson, U.E.; Olde, B.; Leeb-Lundberg, L.M. G-protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol. Pharmacol., 2011, 79, 400-410.
[33]
Madeo, A.; Maggiolini, M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res., 2010, 70, 6036-6046.
[34]
Albanito, L.; Madeo, A.; Lappano, R.; Vivacqua, A.; Rago, V.; Carpino, A.; Oprea, T.I.; Prossnitz, E.R.; Musti, A.M.; Ando, S.; Maggiolini, M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res., 2007, 67, 1859-1866.
[35]
Filardo, E.J.; Quinn, J.A.; Bland, K.I.; Frackelton, A.R., Jr Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol., 2000, 14, 1649-1660.
[36]
Holm, A.; Baldetorp, B.; Olde, B.; Leeb-Lundberg, L.M.; Nilsson, B.O. The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle. J. Vasc. Res., 2011, 48, 327-335.
[37]
Chan, Q.K.; Lam, H.M.; Ng, C.F.; Lee, A.Y.; Chan, E.S.; Ng, H.K.; Ho, S.M.; Lau, K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ., 2010, 17, 1511-1523.
[38]
Wei, W.; Chen, Z.J.; Zhang, K.S.; Yang, X.L.; Wu, Y.M.; Chen, X.H.; Huang, H.B.; Liu, H.L.; Cai, S.H.; Du, J.; Wang, H.S. The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo. Cell Death Dis., 2014, 5, e1428.
[39]
Pandey, D.P.; Lappano, R.; Albanito, L.; Madeo, A.; Maggiolini, M.; Picard, D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J., 2009, 28, 523-532.
[40]
Vivacqua, A.; Bonofiglio, D.; Recchia, A.G.; Musti, A.M.; Picard, D.; Ando, S.; Maggiolini, M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol., 2006, 20, 631-646.
[41]
Kimura, M.; Mizukami, Y.; Miura, T.; Fujimoto, K.; Kobayashi, S.; Matsuzaki, M. Orphan G protein-coupled receptor, GPR41, induces apoptosis via a p53/Bax pathway during ischemic hypoxia and reoxygenation. J. Biol. Chem., 2001, 276, 26453-26460.
[42]
Han, G.; Li, F.; Yu, X.; White, R.E. GPER: A novel target for non-genomic estrogen action in the cardiovascular system. Pharmacol. Res., 2013, 71, 53-60.
[43]
Gaudet, H.M.; Cheng, S.B.; Christensen, E.M.; Filardo, E.J. The G-protein coupled estrogen receptor, GPER: The inside and inside-out story. Mol. Cell. Endocrinol., 2015, 418(Pt 3), 207-219.
[44]
Ahola, T.M.; Manninen, T.; Alkio, N.; Ylikomi, T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology, 2002, 143, 3376-3384.
[45]
Campisi, J.; d’Adda di Fagagna, F. Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell Biol., 2007, 8, 729-740.
[46]
Bolton, J.L.; Thatcher, G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem. Res. Toxicol., 2008, 21, 93-101.
[47]
Thomas, P.; Pang, Y.; Filardo, E.J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology, 2005, 146, 624-632.
39
3